{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:36:36Z","timestamp":1790015796528,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Key Research and Development Program of Hubei Province of China","award":["No. 2021BCA116"],"award-info":[{"award-number":["No. 2021BCA116"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82072736, 82003205, 82373123\uff0c82473175"],"award-info":[{"award-number":["No. 82072736, 82003205, 82373123\uff0c82473175"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Hubei Province of China","award":["No. 2024AFB655"],"award-info":[{"award-number":["No. 2024AFB655"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04084-7","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:28:40Z","timestamp":1762957720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preoperative serum magnesium level as a prognostic and predictive biomarker in locally advanced gastric cancer patients receiving neoadjuvant immunochemotherapy"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiaohang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duofei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixiong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"3","key":"4084_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"10251","key":"4084_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(20)31288-5.","journal-title":"Lancet"},{"issue":"10184","key":"4084_CR3","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1.","journal-title":"Lancet"},{"issue":"9742","key":"4084_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"issue":"10294","key":"4084_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"10111","key":"4084_CR6","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5.","journal-title":"Lancet"},{"key":"4084_CR7","unstructured":"IMFINZI\u00ae (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers. Accessed May 9. 2025. https:\/\/www.businesswire.com\/news\/home\/20250307294024\/en\/IMFINZI-durvalumab-based-regimen-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-event-free-survival-in-resectable-early-stage-gastric-and-gastroesophageal-junction-cancers."},{"issue":"10142","key":"4084_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang YJ, et al. Pembrolizumab versus Paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(18)31257-1.","journal-title":"Lancet"},{"issue":"10","key":"4084_CR9","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571\u201380. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3370.","journal-title":"JAMA Oncol"},{"issue":"2","key":"4084_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(21)00692-6.","journal-title":"Lancet Oncol"},{"issue":"21","key":"4084_CR11","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330(21):2064\u201374. https:\/\/doi.org\/10.1001\/jama.2023.19918.","journal-title":"JAMA"},{"issue":"2","key":"4084_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol. 2023;41(2):255\u201365. https:\/\/doi.org\/10.1200\/JCO.22.00686.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4084_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder AM, Dedeilia A, Sierra-Davidson K, et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. 2024;24(7):498\u2013512. https:\/\/doi.org\/10.1038\/s41568-024-00705-7.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"4084_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071749","volume":"12","author":"IV Zurlo","year":"2020","unstructured":"Zurlo IV, Basso M, Strippoli A, et al. Treatment of locally advanced gastric cancer (LAGC): back to lauren\u2019s classification in Pan-cancer analysis era? Cancers (Basel). 2020;12(7):1749. https:\/\/doi.org\/10.3390\/cancers12071749.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"4084_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101621","volume":"5","author":"H Yamaguchi","year":"2024","unstructured":"Yamaguchi H, Hsu JM, Sun L, Wang SC, Hung MC. Advances and prospects of biomarkers for immune checkpoint inhibitors. Cell Rep Med. 2024;5(7):101621. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101621.","journal-title":"Cell Rep Med"},{"issue":"12","key":"4084_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Humeau J, Buqu\u00e9 A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725\u201341. https:\/\/doi.org\/10.1038\/s41571-020-0413-z.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6349","key":"4084_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313. https:\/\/doi.org\/10.1126\/science.aan6733.","journal-title":"Science"},{"issue":"5","key":"4084_CR18","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"issue":"7357","key":"4084_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature10246","volume":"475","author":"FY Li","year":"2011","unstructured":"Li FY, Chaigne-Delalande B, Kanellopoulou C, et al. Second messenger role for Mg2\u2009+\u2009revealed by human T-cell immunodeficiency. Nature. 2011;475(7357):471\u20136. https:\/\/doi.org\/10.1038\/nature10246.","journal-title":"Nature"},{"issue":"4","key":"4084_CR20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.cell.2021.12.039","volume":"185","author":"J L\u00f6tscher","year":"2022","unstructured":"L\u00f6tscher J, Mart\u00ed I, L\u00edndez AA, Kirchhammer N, et al. Magnesium sensing via LFA-1 regulates CD8\u2009+\u2009T cell effector function. Cell. 2022;185(4):585\u2013e60229. https:\/\/doi.org\/10.1016\/j.cell.2021.12.039.","journal-title":"Cell"},{"issue":"4","key":"4084_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.cell.2021.12.039","volume":"185","author":"J L\u00f6tscher","year":"2022","unstructured":"L\u00f6tscher J, Mart\u00ed i L\u00edndez AA, Kirchhammer N, et al. \u901a\u8fc7 LFA-1 \u7684\u9541\u611f\u5e94\u8c03\u8282 CD8 T \u7ec6\u80de\u6548\u5e94\u529f\u80fd+. Cell. 2022;185(4):585\u2013e60229. https:\/\/doi.org\/10.1016\/j.cell.2021.12.039.","journal-title":"Cell"},{"key":"4084_CR22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.jconrel.2024.06.067","volume":"372","author":"L Ma","year":"2024","unstructured":"Ma L, Wang X, Wu Y, et al. Controlled release of manganese and magnesium ions by microsphere-encapsulated hydrogel enhances cancer immunotherapy. J Controlled Release. 2024;372:682\u201398. https:\/\/doi.org\/10.1016\/j.jconrel.2024.06.067.","journal-title":"J Controlled Release"},{"key":"4084_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev-nutr-071811-150656","volume":"32","author":"WB Weglicki","year":"2012","unstructured":"Weglicki WB. Hypomagnesemia and inflammation: clinical and basic aspects. Annu Rev Nutr. 2012;32:55\u201371. https:\/\/doi.org\/10.1146\/annurev-nutr-071811-150656.","journal-title":"Annu Rev Nutr"},{"issue":"7","key":"4084_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1042\/CS20120086","volume":"123","author":"FI Wolf","year":"2012","unstructured":"Wolf FI, Trapani V. Magnesium and its transporters in cancer: a novel paradigm in tumour development. Clin Sci (Lond). 2012;123(7):417\u201327. https:\/\/doi.org\/10.1042\/CS20120086.","journal-title":"Clin Sci (Lond)"},{"issue":"6","key":"4084_CR25","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1634\/theoncologist.2018-0465","volume":"24","author":"W Liu","year":"2019","unstructured":"Liu W, Qdaisat A, Soliman PT, et al. Hypomagnesemia and survival in patients with ovarian cancer who received chemotherapy with carboplatin. Oncologist. 2019;24(6):e312\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2018-0465.","journal-title":"Oncologist"},{"issue":"1","key":"4084_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00012.2014","volume":"95","author":"JHF de Baaij","year":"2015","unstructured":"de Baaij JHF, Hoenderop JGJ, Bindels RJM. Magnesium in man: implications for health and disease. Physiol Rev. 2015;95(1):1\u201346. https:\/\/doi.org\/10.1152\/physrev.00012.2014.","journal-title":"Physiol Rev"},{"key":"4084_CR27","doi-asserted-by":"publisher","first-page":"100676","DOI":"10.1016\/j.blre.2020.100676","volume":"44","author":"J Gile","year":"2020","unstructured":"Gile J, Ruan G, Abeykoon J, McMahon MM, Witzig T, Magnesium. The overlooked electrolyte in blood cancers? Blood Rev. 2020;44:100676. https:\/\/doi.org\/10.1016\/j.blre.2020.100676.","journal-title":"Blood Rev"},{"issue":"4","key":"4084_CR28","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cncr.33283","volume":"127","author":"W Liu","year":"2021","unstructured":"Liu W, Qdaisat A, Ferrarotto R, et al. Hypomagnesemia and survival in patients with head and neck cancers who received primary concurrent chemoradiation. Cancer. 2021;127(4):528\u201334. https:\/\/doi.org\/10.1002\/cncr.33283.","journal-title":"Cancer"},{"issue":"4","key":"4084_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/apha.13846","volume":"235","author":"LMM Gommers","year":"2022","unstructured":"Gommers LMM, Hoenderop JGJ, de Baaij JHF. Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol (Oxf). 2022;235(4):e13846. https:\/\/doi.org\/10.1111\/apha.13846.","journal-title":"Acta Physiol (Oxf)"},{"issue":"10","key":"4084_CR30","doi-asserted-by":"publisher","first-page":"11235","DOI":"10.1096\/fj.201900839R","volume":"33","author":"LMM Gommers","year":"2019","unstructured":"Gommers LMM, Ederveen THA, van der Wijst J, et al. Low gut microbiota diversity and dietary magnesium intake are associated with the development of PPI-induced hypomagnesemia. FASEB J. 2019;33(10):11235\u201346. https:\/\/doi.org\/10.1096\/fj.201900839R.","journal-title":"FASEB J"},{"issue":"3","key":"4084_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3322\/caac.21657","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264\u201379. https:\/\/doi.org\/10.3322\/caac.21657.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4084_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0013.","journal-title":"JAMA Oncol"},{"issue":"3","key":"4084_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/annonc\/mdv610","volume":"27","author":"BW Kang","year":"2016","unstructured":"Kang BW, Seo AN, Yoon S, et al. Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer. Ann Oncol. 2016;27(3):494\u2013501. https:\/\/doi.org\/10.1093\/annonc\/mdv610.","journal-title":"Ann Oncol"},{"issue":"10302","key":"4084_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(21)01234-4.","journal-title":"Lancet"},{"issue":"6","key":"4084_CR35","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","volume":"17","author":"K Muro","year":"2016","unstructured":"Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717\u201326. https:\/\/doi.org\/10.1016\/S1470-2045(16)00175-3.","journal-title":"Lancet Oncol"},{"key":"4084_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115188","volume":"216","author":"S Kitapli","year":"2025","unstructured":"Kitapli S, Alkan A, Tanriverdi O. Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers. Eur J Cancer. 2025;216:115188. https:\/\/doi.org\/10.1016\/j.ejca.2024.115188.","journal-title":"Eur J Cancer"},{"issue":"6","key":"4084_CR37","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","volume":"7","author":"J Chao","year":"2021","unstructured":"Chao J, Fuchs CS, Shitara K, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7(6):895\u2013902. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0275.","journal-title":"JAMA Oncol"},{"issue":"1","key":"4084_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320. https:\/\/doi.org\/10.1056\/NEJMoa055531.","journal-title":"N Engl J Med"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04084-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04084-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04084-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:28:43Z","timestamp":1762957723000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-04084-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4084"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04084-7","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"18 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Medical Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (Approval No. 2024\u2009\u2212\u20090474). Written informed consent was obtained from all participants prior to their inclusion in the study. All patient data were anonymized and handled with strict confidentiality throughout the study process.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}